EYEspa has released a new guide on the connection between omega-3 fatty acids and eye health, exploring how maintaining ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Perfluorohexyloctane and lotilaner ophthalmic solution, 2 ocular surface disease drugs, have changed the DED and DB treatment paradigms.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, ...

Vision Care market Insights: Rising screen time and aging populations bolster the demand for vision correction solutions, including advanced surgical treatments ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Pre-tax losses at the main Irish unit of eye care product firm, Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023.

The US contact lenses market is expected to grow at a CAGR of $% from 2022 to 2028 with an increasing number of eye inaccuracies among the younger population.

Pre-tax losses at the main Irish unit of eye care product firm Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023.

Dry January is a popular New Year's resolution for many Brits aiming to detox after the festive season's indulgence in mulled wine and eggnog. However, health experts from Universal Drugstore have ...